MedPath

BAVARIAN NORDIC

🇩🇰Denmark
Ownership
-
Established
1992-01-01
Employees
759
Market Cap
$3.1B
Website
http://www.bavarian-nordic.com

A Phase 3 Trial of the CHIKV VLP Vaccine in Children

Phase 3
Not yet recruiting
Conditions
Chikungunya Virus
Interventions
Biological: CHIKV VLP vaccine
Biological: Placebo
First Posted Date
2025-06-04
Last Posted Date
2025-06-04
Lead Sponsor
Bavarian Nordic
Target Recruit Count
720
Registration Number
NCT07003984
Locations
🇺🇸

Velocity Clinical Research-Omaha, Omaha, Nebraska, United States

🇺🇸

Velocity Clinical Research - Salt Lake City, West Jordan, Utah, United States

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Phase 2
Recruiting
Conditions
Encephalitis
Interventions
First Posted Date
2025-03-28
Last Posted Date
2025-06-13
Lead Sponsor
Bavarian Nordic
Target Recruit Count
400
Registration Number
NCT06899802
Locations
🇺🇸

Benchmark Research, San Angelo, Texas, United States

🇺🇸

Lifeline Primary Care, Inc. / CCT Research, Lilburn, Georgia, United States

🇺🇸

Johnson County Clin-Trials, Lenexa, Kansas, United States

and more 4 locations

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Phase 2
Recruiting
Conditions
Monkeypox (Mpox)
Interventions
First Posted Date
2024-08-12
Last Posted Date
2025-02-26
Lead Sponsor
Bavarian Nordic
Target Recruit Count
460
Registration Number
NCT06549530
Locations
🇨🇩

University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the

🇺🇬

Uganda Virus Research Institute, Entebbe, Uganda

🇺🇬

Epicentre Mbarara Research Centre, Mbarara, Uganda

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Phase 3
Active, not recruiting
Conditions
Chikungunya Virus Infection
Interventions
Biological: CHIKV VLP vaccine booster
Biological: Placebo booster
First Posted Date
2023-08-23
Last Posted Date
2025-04-03
Lead Sponsor
Bavarian Nordic
Target Recruit Count
800
Registration Number
NCT06007183
Locations
🇺🇸

Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States

🇺🇸

Optimal Research, LLC, Peoria, Illinois, United States

🇺🇸

Suncoast Research Associates, LLC, Miami, Florida, United States

and more 12 locations

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Phase 3
Completed
Conditions
Chikungunya Virus
Interventions
Biological: Placebo
Biological: CHIKV VLP/adjuvant
First Posted Date
2022-04-27
Last Posted Date
2024-12-13
Lead Sponsor
Bavarian Nordic
Target Recruit Count
413
Registration Number
NCT05349617
Locations
🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

🇺🇸

Suncoast Research Associates, LLC, Miami, Florida, United States

🇺🇸

Global Clinical Research Professionals (GCP), Saint Petersburg, Florida, United States

and more 7 locations

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Phase 3
Completed
Conditions
COVID-19 Disease
Interventions
First Posted Date
2022-04-14
Last Posted Date
2025-02-24
Lead Sponsor
Bavarian Nordic
Target Recruit Count
4205
Registration Number
NCT05329220
Locations
🇺🇸

Achieve Clinical Research LLC d/b/a Accel Research Sites, Birmingham, Alabama, United States

🇺🇸

Arizona Clinical Trials, Mesa, Arizona, United States

🇺🇸

Tucson Neuroscience Research - M3 WR, Tucson, Arizona, United States

and more 44 locations

MVA-BN-RSV Vaccine Trial

Phase 3
Terminated
Conditions
Respiratory Syncytial Virus Infections
Interventions
Biological: MVA-BN-RSV vaccine
First Posted Date
2022-02-14
Last Posted Date
2024-10-31
Lead Sponsor
Bavarian Nordic
Target Recruit Count
20419
Registration Number
NCT05238025
Locations
🇺🇸

North Alabama Research Center, LLC, Athens, Alabama, United States

🇺🇸

Central Alabama Research, Birmingham, Alabama, United States

🇺🇸

Achieve Clinical Research, LLC d/b/a Accel Research Sites, Birmingham, Alabama, United States

and more 109 locations

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

Phase 2
Active, not recruiting
Conditions
COVID-19 Disease
Interventions
Biological: ABNCoV2 100ug
Biological: ABNCoV2 50ug
First Posted Date
2021-10-14
Last Posted Date
2022-10-24
Lead Sponsor
Bavarian Nordic
Target Recruit Count
197
Registration Number
NCT05077267
Locations
🇩🇪

Emovis GmbH, Berlin, Germany

🇩🇪

Velocity Clinical Research Hamburg, Hamburg, Germany

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

Phase 3
Completed
Conditions
Chikungunya Virus
Interventions
Biological: CHIKV VLP/adjuvant
Biological: Placebo
First Posted Date
2021-10-08
Last Posted Date
2023-12-14
Lead Sponsor
Bavarian Nordic
Target Recruit Count
3258
Registration Number
NCT05072080
Locations
🇺🇸

Optimal Research, LLC, Rockville, Maryland, United States

🇺🇸

Alliance for Multispecialty Research - Mobile, Mobile, Alabama, United States

🇺🇸

Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States

and more 33 locations

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

Phase 2
Completed
Conditions
Chikungunya Virus
Interventions
Biological: CHIKV VLP, adjuvanted
First Posted Date
2021-10-04
Last Posted Date
2023-07-03
Lead Sponsor
Bavarian Nordic
Target Recruit Count
25
Registration Number
NCT05065983
Locations
🇺🇸

Johnson County ClinTrials, Lenexa, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath